Vestal Point Capital, LP: BICARA THERAPEUTICS INC (BCAX): Quarterly 13F Position History
As of Q1 2026, Vestal Point Capital, LP reported 5,425,000 shares of BICARA THERAPEUTICS INC (BCAX), worth $107.9M and representing 3.0% of its 13F equity book. Quarter-over-quarter share count change: + 1,850,000 (+51.7%) . The position first appeared in Q3 2024 and has been disclosed across 7 13F-HR filings in Pactolio's tracked window.
- 5,425,000Shares Held (Latest Filing)
- $107.9MReported Market Value (Latest Filing)
- 3.0%Portfolio Weight (% of 13F Equity Book)
- +1,850,000Quarter-over-Quarter Share Change
- +$47.7MQuarter-over-Quarter Value Change
- 5,425,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 7 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 5,425,000 | +1,850,000 | +51.7% | $107.9M | 3.0% | $19.9 |
| Q4 2025 | 3,575,000 | 1,525,000 | -29.9% | $60.2M | 2.2% | $16.8 |
| Q3 2025 | 5,100,000 | +100,000 | +2.0% | $80.5M | 3.7% | $15.8 |
| Q2 2025 | 5,000,000 | +2,231,025 | +80.6% | $46.5M | 2.4% | $9.3 |
| Q1 2025 | 2,768,975 | +2,058,975 | +290.0% | $36.1M | 2.6% | $13.0 |
| Q4 2024 | 710,000 | +285,000 | +67.1% | $12.4M | 0.7% | $17.4 |
| Q3 2024 | 425,000 | — | — | $10.8M | 0.9% | $25.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Vestal Point Capital, LP first disclose a BCAX position in 13F-HR filings?
Vestal Point Capital, LP first reported BICARA THERAPEUTICS INC (BCAX) on its 13F-HR filing for the period ending 2024-09-30 (Q3 2024). The position has appeared on 7 reported quarters within Pactolio's tracked window.
What was Vestal Point Capital, LP's most recent quarter-over-quarter share-count change in BCAX?
Between Q4 2025 and Q1 2026, Vestal Point Capital, LP added 1,850,000 shares of BCAX (+51.7%), bringing the total reported position to 5,425,000 shares at a market value of $107.9M.
Does the implied price-per-share represent Vestal Point Capital, LP's cost basis in BCAX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.